1Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,People's Republic of China.
2Department of Gastroenterology and Urology,Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,People's Republic of China.
Br J Nutr. 2018 Dec;120(12):1359-1369. doi: 10.1017/S0007114518002854. Epub 2018 Oct 29.
The aim of this retrospective study was to investigate the prognostic significance of pre-treatment immunological and nutritional statuses in patients with locally advanced gastric cancer (GC), and to use the risk factors to develop a predictive score. A total of 731 patients who underwent gastrectomy for stage II/III GC from November 2010 to December 2015 were recruited into this retrospective study. On the basis of univariate and further multivariate Cox regression analyses, decreased pretreatment lymphocyte count (<1·5×109/litre) and prealbumin concentrations (<180 mg/l) were identified to be independently associated with poorer overall survival (OS) and disease-free survival (DFS). Low albumin concentrations (<33 g/l) were identified as an independent risk factor only for OS, but not for DFS. Thereafter, patients who had a decreased prealbumin concentration and lymphocyte count were given a combination of serum prealbumin concentration and lymphocyte count (Co-PaL) score of 2. Patients with only one or neither of these concentrations were given a Co-PaL score of 1 or 0, respectively. Both the OS and the DFS time were inversely related to the Co-PaL scores, and the differences among the three groups were all significant. In contrast, the prognosis did not differ significantly between patients with good nutrition and those with mild to moderate malnutrition according to the prognostic nutritional index. This study indicated that the simple scoring system could accurately predict the prognosis of patients who underwent gastrectomy for stage II/III GC. The score might be helpful in terms of clinical preoperative decision-making.
本回顾性研究旨在探讨局部晚期胃癌(GC)患者治疗前免疫和营养状况的预后意义,并利用这些风险因素制定预测评分。本研究共纳入了 2010 年 11 月至 2015 年 12 月接受 II/III 期 GC 胃切除术的 731 例患者。基于单因素和进一步的多因素 Cox 回归分析,发现治疗前淋巴细胞计数(<1.5×109/l)和前白蛋白浓度(<180mg/l)降低与总生存期(OS)和无病生存期(DFS)较差独立相关。低白蛋白浓度(<33g/l)仅被确定为 OS 的独立危险因素,而不是 DFS 的独立危险因素。此后,对于前白蛋白浓度和淋巴细胞计数均降低的患者,给予血清前白蛋白浓度和淋巴细胞计数(Co-PaL)评分 2。仅有一种或均没有这些浓度的患者,分别给予 Co-PaL 评分 1 或 0。OS 和 DFS 时间均与 Co-PaL 评分呈负相关,三组之间的差异均有统计学意义。相比之下,根据预后营养指数,营养状况良好和轻度至中度营养不良的患者之间的预后没有显著差异。这项研究表明,这种简单的评分系统可以准确预测接受 II/III 期 GC 胃切除术患者的预后。该评分可能有助于临床术前决策。